Carbyne Equity Partners

Elicit Plant is an agro-biotech company focused on enhancing the resilience of crops to water stress and developing phytosterol-based solutions. By leveraging proprietary technology, Elicit Plant aims to address the challenges posed by climate change on agriculture. The company’s products are designed to improve plant stress resistance and activate natural defenses, which has been validated through extensive field trials across three continents. These trials demonstrate that Elicit Plant's biosolutions provide farmers with consistent and significant returns on investment, positioning the company as a leader in the ecological transition within the agricultural sector.

Fotokite specializes in developing autonomous aerial systems designed to assist first responders in emergency situations. Their patented technology integrates with fire trucks and public safety vehicles, allowing firefighters to deploy the system with a single button. Once activated, the Fotokite can ascend to heights of 45 meters, delivering critical real-time information through both thermal and standard video feeds. This capability enhances situational awareness without requiring additional personnel to operate the drone, as it operates autonomously. The tethered system ensures continuous power and data transmission, allowing for extended flight times exceeding 24 hours. The aerial data can be live-streamed to other team members at the scene or back at the station, facilitating better communication and more informed decision-making. By providing immediate and detailed insights upon arrival, Fotokite enhances the ability of first responders to assess incidents and deploy resources effectively.

ITM Isotopen Technologien München AG is a biotechnology and radiopharmaceutical company based in Garching, Germany, focusing on the development, manufacturing, and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for cancer treatment. Established in 2004, ITM has built a robust global supply network and accomplished GMP manufacturing capabilities. The company offers a range of products, including EndolucinBeta, a radiopharmaceutical precursor for targeted radionuclide therapy, as well as radionuclides like 225Ac and 213Bi. Additionally, ITM develops automated systems for synthesizing radiolabeled biomolecules and provides GMP radiolabeling services. With a growing portfolio of innovative treatments and partnerships, ITM aims to enhance patient outcomes and quality of life in oncology, specifically addressing conditions such as neuroendocrine cancers and bone metastases while minimizing side effects.